Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy

Table 1

Timeline of treatment.

Treatment	Dose and frequency	Timeline (month/year)	Reason for cessation	Months of therapy
Vemurafenib	960 mg (4 × 240 mg) orally twice daily (BID)	4/2012–9/2014	Progression	29
Ipilimumab	4 cycles induction q3 weeks at 3 mg/kg, followed by maintenance treatment	9/2014–5/2015	Progression	8
Pembrolizumab	2 mg/kg q3 weeks, completed 11 cycles	6/2016–3/2017	Progression	9
Ipilimumab/nivolumab	4 cycles induction ipilimumab 3 mg/kg+nivolumab 1 mg/kg q3 weeks, 2 cycles maintenance nivolumab 240 mg q2 weeks	4/2017–12/2017	Progression	8
Intralesional SD-101+pembrolizumab (study)	8 mg SD-101 injection, pembrolizumab 200 mg q3 weeks	1/2018–3/2018	Progression	3
Dabrafenib/trametinib	Dabrafenib 150 mg BID initially, dose reduced 75 mg BID, trametinib 2 mg daily	3/2018–11/2018	Progression	8
Encorafenib/binimetinib	Encorafenib 450 mg daily, binimetinib 45 mg BID	12/2018–4/2019	Progression	4
Ipilimumab/nivolumab retreatment	4 cycles induction 3 mg/kg ipilimumab+1 mg/kg nivolumab q3 weeks, 5 cycles maintenance nivolumab 480mg q4 weeks	4/2019–present (12/2019)		Ongoing treatment for 8 months